Romuald Harwas graduated from the Cracow University of Economics at the Faculty of Management with a specialization in accounting.
He has extensive experience in finance. He was a management accountant, financial controller, and later financial director and member of the management and supervisory boards of companies, including those listed on the Warsaw Stock Exchange (GPW). From the beginning of his career, he has been closely associated with the pharmaceutical and biotechnology industry.
In Poland, he worked for such well-known companies as Cormay, TVN, Luxmed, Pure Biologics, and Synektik. He spent over six years abroad, working for the Australian company Bradken, among others, and serves on the Board of Directors of WPD Pharmaceuticals Inc., a company listed on the Canadian Securities Exchange (CSE). He has a long history of working with various stakeholder groups, such as auditors, banks, insurance companies, investors, grant institutions (NCBR, ABM, PARP), and public market institutions (GPW, KNF). He led the transition of companies from NewConnect to the main market of the GPW and several prospectus processes on the GPW.
He is a specialist in management, accounting and economic analysis, shapes and implements financial strategies, ensuring companies ‘financial liquidity, profitability and development.